Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy


  • Gian Luca Breschi Hetegy, Health Economics Strategy & Analytics, Turin - Italy
  • Federica Demma Takeda Italia S.p.A., Rome - Italy
  • Paolo Morelli Takeda Italia S.p.A., Rome - Italy
  • Maria De Francesco Hetegy, Health Economics Strategy & Analytics, Turin - Italy



Brentuximab vedotin, Cost-analysis, Economic evaluation, Hodgkin Lymphoma, Italian NHS



Introduction: In Hodgkin Lymphoma (HL), the early administration of brentuximab vedotin (BV) represents a highly effective treatment to consolidate patients after autologous stem cell transplantation (ASCT). For this indication, the Summary of Product Characteristics (SPC) reports a lower medical resource utilization in BV vs. placebo. This study aimed at assessing costs accrued by using BV in consolidation after ASCT and compare them with the resource consumption associated with the main options today used in Italy for HL.

Methods and results: A cost-analysis based on patients at high risk of relapse (HL CD30+-HR) after ASCT was developed by collecting data about health care consumption (drugs and monitoring). The model is described by two arms, "A," where BV is used as consolidation therapy after ASCT, and "B", where patients are treated only at the time of relapse. A 3-year time horizon and the Italian National Health System perspective were adopted. All data inputs for the analysis were sourced from the available literature and official list prices. The simulation was integrated by sensitivity analysis. The introduction of BV as consolidation therapy would allow savings in terms of drug acquisition and resource consumption. Over a 3-year time frame, the Consolidation arm’s overall expenditure was 137,059€ vs. 225,418€ in the Non-consolidation arm. Early after the ASCT, BV administration guarantees a long period free from relapses (5-year PFS is not reached), thus reducing the clinical and economic burden of the subsequent therapies needed to treat further relapses.

Conclusions: The present pharmacoeconomic analysis shows that the introduction of BV as consolidation therapy after ASCT represents a sustainable expenditure for the National Healthcare System (NHS) and a cost-saving paradigm when compared with the drug mainly used for treating the relapses.


de Leval L, Gaulard P. CD30+ lymphoproliferative disorders. Haematologica. 2010;95(10):1627-1630. PMID:20884717 DOI:

AIRTUM. The burden of rare cancers in Italy. Riv. dell’Associazione Ital. di Epidemiol. (2016).

Coviello V, Buzzoni C, Fusco M, et al; AIRTUM Working Group. Survival of cancer patients in Italy. Epidemiol Prev. 2017;41(2)(suppl 1):1-244. PMID:28629213

Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183-1194. PMID:29229594 DOI:

Lapuz C, Enjeti AK, O’Brien PC, Capp AL, Holliday EG, Gupta SA. Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era. Blood Lymphat Cancer. 2018;8:13-20. DOI:

Eichenauer DA, Aleman BMP, André M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19-iv29. DOI:

Bazarbachi A, Boumendil A, Finel H et al, Evolution of outcome over time for relapsed Hodgkin lymphoma after autologous stem cell transplant: Improved survival for early relapse in recent years. Blood. 2020;136(Supplement 1):9-10. DOI:

Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531-2533. PMID:23617324 DOI:

EMA, E. Allegato I Riassunto delle caratteristiche del prodotto, Adcetris. (2018).

Moskowitz CH, Nademanee A, Masszi T, et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862. PMID:25796459 DOI:

Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-2642. PMID:30266774 DOI:

AETHERA CSR, data on file

Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—1. Value Health. 2012;15(6):796-803. PMID:22999128 DOI:

Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183-2189. PMID:22454421 DOI:

Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562-1566. PMID:27432875 DOI:

Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol. 2018;36(14):1428-1439. PMID:29584546 DOI:

AIFA. Agenzia Italiana del Farmaco. Regime di rimborsabilità e prezzo di vendita del medicinale per uso umano «Adcetris». Gazzetta n. 143 del 23 giugno 2014. Determina n. 607/2014.Determina 2018.

AIFA. Agenzia Italiana del Farmaco. Regime di rimborsabilità e prezzo di vendita del medicinale per uso umano «Opdivo». Gazzetta n. 295 del. 17 dicembre 2019 Determina n. 1799/2019. (2019).

Radford J, McKay P, Malladi R, et al. Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. Bone Marrow Transplant. 2017;52(3):452-454. PMID:28092356 DOI:

Younes A, Santoro A, Shipp M et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study. Lancet Oncol. 2016; 17(9): 1283-94. DOI:

Cheah CY, Chihara D, Horowitz S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016;27(7):1317-1323. PMID:27091808 DOI:

Alinari L, Blum KA. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant. Blood. 2016;127(3):287-295. DOI:

Gazzetta Ufficiale numero 156 del 7 Luglio 2006. Supplemento Ordinario n.161.

Gazzetta Ufficiale numero 227 del 29 Settembre 2006.

Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. PMID:3657876 DOI:

Collins GP, Parker AN, Pocock C, et al; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol. 2014;164(1):39-52. PMID:24117159 DOI:

Ng M, Waters J, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer. 2005;92(8):1352-1357. PMID:15812553 DOI:

El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363-1368. DOI:

Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin’s disease: long-term results. Br J Cancer. 1990;62(2):279-285. DOI:

Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anticancer Drugs. 2001;12(9):725-729. PMID:11593053 DOI:

Diehl V, Sieber M, Rüffer U et al; German Hodgkin's Lymphoma Study Group. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol. 1997;8(2):143-148. DOI:

Josting A, Rudolph C, Reiser M, et al; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10):1628-1635. PMID:12377653 DOI:

NICE. Single Technology Appraisal Brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma. Committee Papers [ID722]. (2016).

Regione Emilia Romagna. Tariffa unica convenzionale per le prestazioni di assistenza ospedaliera regole e tariffe valide per l’anno 2009 secondo cms-drg versione 24. (2009).

Regione Emilia Romagna. Specifiche tecniche per l’applicazione delle tariffe n.317 del 30 ottobre 2014.

Regione Lombardia. Deliberazione N° IX/2946, Seduta del 25 gennaio 2012. Tariffario prestazioni ambulatoriali. (2012).

Regione Piemonte. Nomenclatore giugno 2013. (2013).

Regione Puglia. Bollettino Ufficiale della Regione Puglia n. 94 del 16 luglio 2014.;jsessionid=FFAE47282A9BB27BF999A0EE22FCD5CB.

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (ID972). Second appraisal committee meeting Chair's presentation. 12 April 2017

Lalibertè F, Raut M, Duh M, et al. Real-world healthcare resource utilization (HRU) of classical Hodgkin Lymphoma (cHL) patients (pts) treated with anti-PD1 checkpoint inhibitors in the United States (US). Hematol Oncol. 2019;37:495-496. DOI:

Hoppe RT, Advani RH, Ai WZ, et al. NCCN guidelines® insights Hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2018;16(3):245-254. DOI:

Bonafede M, Feliciano J, Cai Q, et al. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. Clinicoecon Outcomes Res. 2018;10:629-641. PMID:30410373 DOI:

Shao C, Liu J, Zhou W, et al. Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2019;60(4):947-954. DOI:

Gazzetta Ufficiale, numero 23; 28 gennaio 2013; Supplemento n.8; Ministero della Salute. Tariffario prestazioni ambulatoriali. (2013).

Ministero della salute. Rapporto annuale sull’attività di ricovero ospedaliero, Dati SDO 2017.

Ministero della Salute 2007. Progetto Mattoni SSN. Pronto Soccorso e sistema 118. Proposta metodologica per la valutazione dei costi dell’emergenza. (2007).

Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, et al. Immunotherapy in Hodgkin lymphoma: present status and future strategies. Cancers (Basel). 2019;11(8):E1071. PMID:31362369 DOI:

Sureda A, André M, Borchmann P, et al. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer. 2020;20(1):1088. PMID:33172440 DOI:

Brentuximab (Adcetris) for Hodgkin Lymphoma—Resubmission, pan-Canadian Oncology Drug Review Final Economic Guidance Report, Feb. 2018, (2018).

AIFA. Agenzia Italiana del Farmaco Regime di rimborsabilità e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano «Keytruda». Gazzetta n. 290 del 27 novembre 2019. Determina n. 1763/2019.Determina 2019. (2019).

Yasenchak CA, Tseng WY, Yap M, Rembert D, Patt DA. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leuk Lymphoma. 2015;56(11):3143-3149. PMID:25860233 DOI:

Hansen RN, Ramsey SD, Slejko J, Carlson JJ. The cost of relapse in Hodgkin lymphoma. J Clin Oncol. 2014;32(15 suppl):e17537. DOI:



How to Cite

Breschi GL, Demma F, Morelli P, De Francesco M. Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy. abtpn [Internet]. 2021 Sep. 2 [cited 2022 Jul. 1];8(1):81-7. Available from:



Original research article